Acute stent thrombosis associated with heparin-induced thrombocytopenia and abciximab-induced profound thrombocytopenia

J Invasive Cardiol. 2011 Feb;23(2):E5-8.

Abstract

Heparin-induced thrombocytopenia (HIT) is a wellknown complication after exposure to heparin products. Profound thrombocytopenia has also been reported with the use of abciximab, a glycoprotein IIb/IIIa receptor antagonist, which is used during percutaneous coronary intervention. Acute stent thrombosis is a rare but serious complication of HIT. We report an unusual case of acute stent thrombosis with concomitant heparin- and abciximab-induced profound thrombocytopenia and discuss the subsequent treatment strategies. Prompt identification and management of this disorder is critically important to avoid devastating complications.

Publication types

  • Case Reports

MeSH terms

  • Abciximab
  • Acute Disease
  • Adult
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Angioplasty, Balloon, Coronary / methods
  • Antibodies, Monoclonal / adverse effects*
  • Anticoagulants / adverse effects
  • Coronary Angiography
  • Coronary Thrombosis / diagnostic imaging*
  • Coronary Thrombosis / etiology*
  • Coronary Thrombosis / therapy
  • Heparin / adverse effects*
  • Humans
  • Immunoglobulin Fab Fragments / adverse effects*
  • Male
  • Myocardial Infarction / therapy
  • Platelet Aggregation Inhibitors / adverse effects
  • Stents / adverse effects*
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / complications*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Heparin
  • Abciximab